Related Experiment Videos
Insights
Carvedilol, a novel beta-blocker for heart failure, shows mixed results on mortality and conflicting symptom benefits. Gradual introduction minimizes adverse effects, but its exact role in heart failure treatment remains unclear.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Carvedilol is the first beta-blocker approved in France for heart failure treatment.
- Initial studies demonstrated improvements in hemodynamic parameters in small patient groups.
Purpose of the Study:
- To evaluate the efficacy and safety of carvedilol in heart failure management.
- To assess the impact of carvedilol on overall mortality and symptom-based criteria.
Main Methods:
- A placebo-controlled, double-blind trial with 1,094 patients.
- An additional trial involving 415 patients with longer follow-up.
Main Results:
- One trial showed a 4.6% absolute reduction in overall mortality after 6.5 months.
- Another trial did not find a significant mortality benefit with longer follow-up.
- Results for symptom improvement were conflicting.
Conclusions:
- Carvedilol's benefit on mortality is not consistently demonstrated across studies.
- Adverse effects are minor and infrequent with gradual dose titration.
- The precise role of carvedilol in heart failure treatment requires further documentation.
Abstract:
(1) Carvedilol is the first betablocker to obtain approval in France for the treatment of heart failure. (2) The improvement in haemodynamic parameters was initially documented in three methodologically sound studies involving a total of 156 patients, with follow-up limited to 16 weeks. (3) A placebo-controlled, double-blind trial involving 1,094 patients showed a beneficial impact on overall mortality of 4.6% in absolute terms after a median follow-up of 6.5 months. This benefit was not found in another trial involving 415 patients followed for 19 months on average. Results for symptom-based criteria are conflicting. (4) When treatment is introduced very gradually, adverse effects seem to be minor (malaise) and infrequent. (5) The place of carvedilol in the treatment of heart failure is not yet precisely documented.